TY - JOUR T1 - Metastatic bronchopulmonary carcinoid JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p2820 AU - Filip Triest AU - Kristiaan Nackaerts AU - Christophe Dooms Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p2820.abstract N2 - Background: Bronchopulmonary carcinoids (BPCs) are rare neuroendocrine tumors. Metastatic BPC (M-BPC) represents less than 10% of all BPCs.Aims: A retrospective study of a 5 years' consecutive series of M-BPC patients, treated in a tertiary referral center.Methods: Demographics, symptoms, staging, pathology, therapy and survival were compared for non-metastatic (NM-) and M-BPC.Results: Of 57 BPC patients, 12 (21%) had metastases. Five were truly metastatic at diagnosis. No differences were observed for age, smoking status and gender. Hemoptysis was mostly found in M-BPC (4/12); infection and absence of symptoms in NM-BPC (both 16/45). Somatostatin receptor imaging was performed in respectively 20% and 92%, FDG-PET in 67% and 75%, Ki-67 staining in 24% and 75%, chromogranin A staining in 64% and 83% of NM- and M-BPC patients. M-BPC was predominantly treated with chemotherapy (42%) and somatostatin analogues (58%), NM-BPC with surgery (91%). Median survival was 52 months for M-BPC, while not yet reached for NM-BPC patients (p=0.01).Conclusions: In our center, a larger proportion of M-BPC patients was treated compared to literature. Major differences between NM-BPC and M-BPC were observed for treatment choices. Survival was significantly worse for M-BPC, although much better compared to more common lung cancer types. ER -